The NPM package for Axios, a popular JavaScript HTTP client library, was briefly compromised this week, possibly by North ...
As of March 23, 2026, ProMIS Neurosciences, Inc. had a $159.4 million market capitalization, putting it in the 26th percentile of companies in the Biotechnology industry. ProMIS Neurosciences, Inc.
Prediction markets allow consumers to trade event contracts tied to real-world outcomes, from elections to economic data and ...
The massive real estate marketplace just changed its tune around pre-market listings, shifting the landscape for brokers and ...
"We are extremely pleased with the significant progress our team achieved in 2025 and the strong momentum we have carried into 2026," said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. ...
Cookie-gated PHP webshells use obfuscation, php-fpm execution, and cron-based persistence to evade detection in Linux hosting ...
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early ...
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results